Orforglipron: Australia’s first non-peptide oral GLP-1

Description

In this Product Explainer, Endocrinologist Dr Ted Wu examines how Orforglipron broadens access to GLP-1 therapy with an oral formulation, reviewing efficacy data, safety findings, and practical guidance for use in clinical practice (6 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Ted Wu

Dr Ted Wu

Oral GLP1s – What GPs Need to Know

Dr Paige Lanyon-Roberts

Dr Paige Lanyon-Roberts

The New Oral Medications for Obesity – A Practical Guide for GPs

Dr Katherine Spira

Dr Katherine Spira

Menstrual Migraine

Prof Danny Green

Prof Danny Green

GLP1s and Muscle Mass – What Does the Evidence Show?

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Ted Wu

expert

Dr Ted Wu

Senior Specialist Endocrinologist; Director, Royal Prince Alfred Hospital Diabetes Centre; Director of Physician Training, Royal Prince Alfred Hospital, Sydney

Date published: 17 November 2026